NICE Ltd
- Country
- 🇮🇱Israel
- Ownership
- -
- Employees
- 8.3K
- Market Cap
- -
- Introduction
NICE Ltd. engages in the provision of enterprise software solutions and services. It operates through the following segments: Customer Engagement, and Financial Crime and Compliance Solutions. The Customer Engagement segment provides suites such as compliance and risk, workforce optimization, operational efficiency, customer experience, and sales and retention. The Financial Crime and Compliance Solutions segment includes for enterprise risk management, anti-money laundering, fraud prevention, and brokerage compliance services. The company was founded on September 28, 1986 and is headquartered in Raanana, Israel.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
26
Drug Approvals
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
News
NHS Approves Breakthrough Bladder Cancer Treatment That Doubles Survival Rates
The NHS has approved enfortumab vedotin combined with pembrolizumab for bladder cancer patients, marking one of the most significant advances in decades for this difficult-to-treat disease.
NICE Recommends Major Shift in Type 2 Diabetes Treatment with Earlier Access to SGLT-2 Inhibitors and Weight Loss Drugs
The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending SGLT-2 inhibitors as first-line treatment for type 2 diabetes patients, potentially saving 22,000 lives once 90% uptake is achieved.
NICE Recommends First NHS Treatment for Rare Eye Disease LHON, Ending Access Disparity in England
NICE has recommended idebenone (Raxone) as the first NHS treatment for Leber's hereditary optic neuropathy (LHON) in England, benefiting an estimated 250 eligible patients aged 12 and over.
NICE Recommends Vanzacaftor-Tezacaftor-Deutivacaftor for Cystic Fibrosis Treatment in England
NICE has approved vanzacaftor-tezacaftor-deutivacaftor (Alyftrek) for NHS funding in England to treat cystic fibrosis in patients aged 6 years and older with at least one F508del mutation.
NICE Approves First-in-Class Birch Pollen Immunotherapy for Severe Hayfever on NHS
NICE has recommended Itulazax 12 SQ-Bet, an under-the-tongue immunotherapy tablet containing birch pollen extract, for NHS use in England for patients with severe hayfever unresponsive to conventional treatments.
ALK's Tree Pollen Tablet ITULAZAX Receives NICE Recommendation for UK NHS Reimbursement
ALK's tree pollen tablet ITULAZAX has been recommended by NICE for use in the UK health system, making it eligible for general reimbursement through the NHS in England, Wales, and Northern Ireland.
Empagliflozin Demonstrates Cost-Effectiveness in Chronic Kidney Disease Treatment, EMPA-KIDNEY Analysis Shows
A new analysis from the EMPA-KIDNEY trial demonstrates that empagliflozin is cost-effective for chronic kidney disease treatment, improving quality-adjusted life years while reducing healthcare costs.
Scottish Health Authority Approves Theramex's Abaloparatide for High-Risk Osteoporosis Treatment
The Scottish Medicines Consortium has recommended Theramex's Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women at very high risk of fracture through NHS Scotland.
Outlook Therapeutics Approaches Critical FDA Decision for LYTENAVA as European Launch Validates Market Potential
Outlook Therapeutics awaits FDA decision by August 27, 2025, for LYTENAVA (bevacizumab-vikg), which would be the first FDA-approved ophthalmic formulation of bevacizumab in the U.S. with 12 years of regulatory exclusivity.
BMJ Investigation Uncovers Data Integrity Issues in AstraZeneca's Ticagrelor Heart Drug Trials
A BMJ investigation has revealed evidence of serious misreporting in two clinical trials that were pivotal to ticagrelor's approval by the FDA and UK regulators.